We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biochemical Hypoglycemia Associated with Risk of Hypoglycemia

By LabMedica International staff writers
Posted on 24 Jan 2019
Print article
Image: Testing blood glucose regularly allows for glycemic control strategy (Photo courtesy of the American Academy of Family Physicians).
Image: Testing blood glucose regularly allows for glycemic control strategy (Photo courtesy of the American Academy of Family Physicians).
To optimize diabetes management, it is essential to have assessments of both hyperglycemia and hypoglycemia. Glycated hemoglobin (HbA1c) is primarily a measure of hyperglycemia, but it provides no indication of the frequency or severity of hypoglycemia.

However, combining HbA1c with continuous glucose monitoring (CGM) provides not only measures of hypoglycemia and hyperglycemia but also information about the patterns of glycemia over the course of the day. Severe hypoglycemia (SH) may result in a variety of symptoms including clumsiness, trouble talking, confusion, loss of consciousness, seizures or death. A feeling of hunger, sweating, shakiness and weakness may also be present.

Scientists at the Jaeb Center for Health Research (Tampa, FL, USA) and their colleagues, analyzed data collected from Diabetes Control and Complications Trial. Glycemic data used in the analyses included the quarterly 7-point glucose measurements and recorded SH events. The 7-point testing consisted of blood samples collected in capillary tubes pre- and 90 min post meals and at bedtime that were sent to the central laboratory. For each 7-point testing day, the frequency of values <70 and <54 mg/dL was computed.

The team found that the risk of SH during a 3-month period was substantially higher when there was at least one hypoglycemic blood glucose value in the preceding 7-point profile, with similar results seen for both the 70 mg/dL (rate ratio = 3.0) and 54 mg/dL (rate ratio = 2.7) thresholds. The risk of an SH event during the 3-month period was more than twofold greater when there was at least one hypoglycemic blood glucose measurement on the 7-point testing, and risk increased further when there was more than one hypoglycemic blood glucose concentration.

The authors concluded that the occurrence of biochemical hypoglycemia <70 or <54 mg/dL is associated with an increased risk of SH. For this reason as well as the deleterious effects of hypoglycemia on glucose counter-regulation and hypoglycemia awareness, cognition, quality of life, and arrhythmias, it is important in diabetes management to avoid hypoglycemic glucose levels as much as possible. Satish Garg, MD, a Professor of Medicine and Pediatrics, said, “Severe hypoglycemia is a significant hurdle for intensifying insulin therapy in patients with T1D. Beck and colleagues emphasize the increased risk of future severe hypoglycemia in patients with any level of biochemical hypoglycemia.” The study was published on January 8, 2019, in the journal Diabetes Technology & Therapeutics.

Related Links:
Jaeb Center for Health Research

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.